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Abstract
Toxoplasma gondii is an obligate intracellular protozoan parasite that can infect most warm-blooded
animals and cause severe and life-threatening disease in developing fetuses and in immune-
compromised patients. Although Toxoplasma was discovered over 100 years ago, we are only now
beginning to appreciate the importance of the role that parasite modulation of its host has on parasite
growth, bradyzoite development, immune evasion, and virulence. The goal of this review is to
highlight these findings, to develop an integrated model for communication between Toxoplasma
and its host, and to discuss new questions that arise out of these studies.
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Toxoplasma gondii is an obligate intracellular protozoan parasite that can infect most warm-
blooded animals. It is ubiquitous throughout the world and estimated to infect approximately
half of the world's population. Toxoplasma is a member of the phylum Apicomplexa, which
encompasses intracellular parasites characterized by a polarized cell structure and two unique
apical secretory organelles named micronemes and rhoptries (1).
Studies on Toxoplasma are spurred on for two important reasons. First, Toxoplasma can cause
severe and life-threatening disease (e.g. encephalitis, retinitis, and myocarditis) in developing
fetuses and in immune-compromised patients. Although current available drugs can treat
Toxoplasma infections, they are poorly tolerated, have severe side effects, and cannot act
against chronic Toxoplasma infections. In addition, resistance to some of these drugs has
recently been noted (2–4). Second, Toxoplasma is used as a model system for other disease-
causing Apicomplexan parasites including Plasmodium, the causative agent of malaria;
Eimeria, which is the cause of poultry coccidiosis; and Cryptosporidium, which is another
important opportunistic infection in AIDS patients (5,6).
Toxoplasma has a complex life cycle consisting of a sexual cycle in its feline definitive hosts
and an asexual cycle in its intermediate hosts (7). Intermediate hosts, including humans, can
be infected by ingestion of oocysts shed in cat feces. Unlike most other Apicomplexan
parasites, Toxoplasma can be transmitted between intermediate hosts by either vertical
(mother–fetus) or horizontal (carnivorism) transmission.
Toxoplasma exists, in intermediate hosts, in two interconvertable stages: bradyzoites and
tachyzoites. Bradyzoites are the slow-growing, transmissible, and encysted form that are
dormant (8). Infections with bradyzoite-containing cysts occur upon ingestion of undercooked
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meat. The wall of these cysts is digested inside of the host stomach and the released bradyzoites,
which are resistant to gastric peptidases, will subsequently invade the small intestine. Within
the small intestine they convert into tachyzoites, which is the rapidly growing, disease-causing
form. Tachyzoites, which can infect most nucleated cells, replicate inside a parasitophorous
vacuole (PV), egress, and then infect neighboring cells. These tachyzoites activate a potent
host immune response that eliminates most of the parasites. Some tachyzoites, however, escape
destruction and convert back into bradyzoites. In the absence of an adequate immune response,
tachyzoites will grow unabated and cause tissue destruction, which can be severe and even
fatal. However, the inflammatory immune response induced by tachyzoites can cause immune-
mediated tissue destruction. Therefore, a subtle balance between inducing and evading the
immune response is crucial for Toxoplasma to establish a chronic infection.
The success of Toxoplasma as a widespread pathogen is due to the ease in which it can be
transmitted between intermediate hosts. Once inside a host the parasite has developed powerful
tools to modulate its host cell and to develop into a chronic infection that can evade the host's
immune system as well as all known anti-toxoplasmotic drugs. The ability of the parasite to
replicate within a host cell, evade immune responses, and undergo bradyzoite development
requires that the parasite effectively modulates its host. Recent work from several laboratories
indicates that there are two major types of communication between Toxoplasma and its host.
The first type is critical for parasite growth or bradyzoite development and does not appear to
differ among distinct Toxoplasma strains. The second type of communication between
Toxoplasma and its host differs among distinct Toxoplasma strains and likely results in strain-
specific differences in pathogenesis. The goal of this review will be to highlight these findings,
to develop an integrated model for communication between Toxoplasma and its host, and to
discuss new questions that arise out of these studies.
TOXOPLASMA HIJACKS HOST ORGANELLES AND CYTOSKELETON
Toxoplasma invasion is a complex process consisting of multiple, independently regulated
steps. First, parasites attach loosely to the host cell's surface. This low affinity interaction is
likely mediated by parasite surface proteins, most of which are GPI-linked proteins named
SAGs (surface antigens), SRSs (SAG-related sequences), and SUSAs (SAG-unrelated surface
antigens) (9,10). Toxoplasma's unique ability to infect almost any nucleated cell and the large
number of surface proteins expressed by tachyzoites suggests that loose attachment may be
mediated by more than a single host molecule. Specific host receptors for any parasite surface
protein have yet to be identified, although some SAGs appear to interact with sulfated
glycosaminoglycans such as heparin (11–13).
Following attachment, an unknown signal triggers an increase in cytosolic calcium, which
eventually stimulates microneme discharge. Although most of the players leading to
microneme release are unknown, there is evidence that calcium-dependent protein kinases
(CDPK) are involved; a Toxoplasma CDPK (TgCDPK1) that can regulate motility and invasion
has been described (14) and purfalcamine, a compound that inhibits a Plasmodium CDPK, also
inhibits Toxoplasma invasion (15). In addition to TgCDPK1, the Toxoplasma genome predicts
the presence of several other CDPK that may also regulate microneme secretion and parasite
invasion (16). At least 20 micronemal proteins have been identified and many of these are
either transmembrane adhesins or accessory proteins for these adhesins (17).
Micronemal adhesin binding to host cells results in tight attachment between the parasite and
the host cell (18). The parasite then uses a unique form of motility called gliding motility that
is powered by the parasite's actomyosin machinery and is thought to be important for invasion
(19,20). At some point, a second unknown trigger stimulates parasites to exocytose proteins
from a second apical secretory organelle called the rhoptry. Four proteins, (RON2, RON4,
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RON5, and RON8), localized to an elongated section of the rhoptries named the rhoptry neck,
bind a micronemal protein named AMA1 after they are secreted (21,22). Together, these
proteins form the moving junction, which is a complex on the host cell plasma membrane that
migrates down the length of the parasite as invasion proceeds. It has been hypothesized that at
least one component of the RON2, 4, 5, 8 complex traverses across the host plasma membrane
and is exposed to the host cytoplasm (21).
As a parasite penetrates into its host cell it enters into the PV that forms concomitantly with
invasion. Morphological and electro-physiological studies demonstrated that the lipids used to
develop the PV are largely derived from the host plasma membrane and not from intracellular
host organelles such as lysosomes, endoplasmic reticulum, and Golgi (23). Toxoplasma
actively defines the protein composition of the PV by preventing the accumulation of most
host transmembrane, but not GPI-linked, proteins (24,25). How this membrane partitioning is
achieved is unknown as is its significance. It is, however, tempting to speculate that exclusion
of host transmembrane proteins from the growing PV underlies the mechanism by which the
parasite escapes the host endolysosomal system.
Although much progress has been made on defining the parasite machinery needed for
invasion, little is understood about host cell structures involved in parasite invasion. Besides
not knowing the host surface proteins that interact with micronemal adhesins or the moving
junction complex, it is also not clear whether the parasite can invade any region of the plasma
membrane or whether it searches for regions enriched in specific lipids and/or proteins.
Another outstanding question is whether the host plasma membrane, like the parasite's, needs
to be anchored at the moving junction. The host actin cytoskeleton is one candidate to fill this
role given its well-established role as a critical regulator of plasma membrane dynamics (26).
In addition, two rhoptry proteins, Toxofilin and RON8, have been identified that interact with
the host actin cytoskeleton and are exposed to the host cytoplasm during infection (21,27,28).
But inhibitors of the actin cytoskeleton, which block parasite invasion, target parasite, but not
host, actin (19). Thus, host actin may have a more subtle role during invasion and/or other host
cytoskeletal elements like microtubules or intermediate filaments may also be important for
invasion. If the host's cytoskeleton is important for invasion, how does the parasite act to
regulate this structure? The most probable model involves a protein localized to the moving
junction that interacts with the host cytoskeleton. Whether these are rhoptry proteins like
Toxofilin and RON8 or a host protein is an unanswered but important question. A recent report
showing that the host Arf6 GTPase localizes to the PV may provide some clues to these
questions because this GTPase is an important regulator of membrane trafficking and the actin
cytoskeleton (29,30).
TOXOPLASMA NUTRIENT ACQUISITION AND METABOLISM DURING
INTRACELLULAR GROWTH
All vacuolar pathogens face the challenge of scavenging nutrients from their host cells. Past
biochemical studies coupled with bioinformatic analysis of the parasite's genome has identified
a number of nutrients that Toxoplasma cannot synthesize de novo but must scavenge. These
include small molecules such as glucose, arginine, iron, tryptophan, and purine nucleosides
that can freely diffuse across the PV and then are presumably pumped into the parasite by
membrane transporters (31–35). While most of these transporters have not yet been identified,
a glucose transporter was cloned and characterized by heterologous expression in Xenopous
oocytes (36).
But how Toxoplasma uses glucose as an energy source is, however, not clear. The parasite's
genome indicates the presence of a full complement of glycolytic and Kreb's cycle enzymes.
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In addition, Toxoplasma can efficiently perform oxidative phosphorylation (37). In contrast,
pyruvate dehydrogenase, which converts pyruvate to acetyl-CoA is localized not to the
mitochondrion but to another DNA-containing membrane-bound organelle, the apicoplast
(38). Most significantly, parasite growth is only mildly affected in the absence of a functional
Kreb's cycle. This is consistent with earlier findings showing that glucose is primarily broken
down to lactic and acetic acids (39,40). Thus, it appears that Toxoplasma generates most of its
ATP via substrate-level phosphorylation. But some of the prescribed anti-toxoplasmotic drugs
(e.g. atovaquone) act by inhibiting the parasite's mitochondrial electron transport (37).
Therefore, it is possible that the slight affect on parasite growth seen in the citric acid cycle
mutant may still have a dramatic affect on in vivo growth and virulence.
In contrast to glucose and other small nutrients that passively diffuse across the PV and then
are pumped into the parasite, other nutrients are obtained by more active, parasite-driven
mechanisms. For example, Toxoplasma redirects LDL-mediated cholesterol transport to the
PV by redirecting host microtubules and microtubule-based transport towards the PV (41).
Electron micrographs show that host microtubules push into the PV and form elongated
membranous tubules that contain LDL-loaded cholesterol. These membrane tubules are
wrapped with a parasite-derived protein complex that includes the dense granule protein
GRA7. This wrapping appears similar to dynamin and dynamin-like proteins that facilitate
pinching off of vesicles from larger membranes. Recombinant GRA7 in vitro can stimulate
liposome tubulation, suggesting that GRA7 may be involved in driving PV tubulation in
vivo (41). But how the parasite internalizes cholesterol once it reaches the PV is still unknown.
In addition to microtubules, host intermediate filaments are also reorganized around the PV
but whether this is important in nutrient acquisition is not known (42).
Dr. David Roos and his colleagues have spearheaded an in silico effort to use Toxoplasma
genomic sequence data (available at http://toxodb.org/toxo/) to develop metabolic pathway
reconstruction maps (see
http://rooscompbio2.bio.upenn.edu/~fengchen/pathway_comparison_2/map01100.html).
These studies have helped define many of the nutrients that the parasite can synthesize de
novo; however, the parasite still scavenges some of these nutrients from its host. For example,
host-derived lipoic acid is metabolized by the parasite's mitochondrion even though lipoic acid
is synthesized and used in the apicoplast (43). Why the parasite needs to scavenge lipoic acid
from host cells is not clear but could be because of a lack of a lipoic acid transporter to export
the nutrient out of the apicoplast.
How does the parasite ensure that it has access to host nutrients synthesized in host
mitochondria and other organelles? One possible way is to relocalize host mitochondria and
endoplasmic reticulum, which synthesize some of the nutrients the parasite needs, to the PV
(44). Recruitment of these organelles occurs quickly after a parasite invades a cell. Antisense
RNA-based assays indicated that the ROP2 rhoptry protein acts to recruit mitochondria (45).
ROP2 has an N-terminal domain that interacts with host mitochondria and a C-terminal portion
that was originally proposed to span across the PV (45). This model has recently been
challenged by the finding that proteins closely related to ROP2 are secreted into the host
cytoplasm and interact with the PV as peripheral membrane proteins (46). Whether ROP2 and
ROP2 family members (e.g. ROP3, ROP4, and ROP7) play similar functions in mediating
organelle recruitment remains to be determined.
Another important, but less studied aspect of the interaction between Toxoplasma and its host
is ensuring that the host has enough nutrients not only for the parasite but also for itself. Previous
microarray studies surprisingly demonstrated an increase in host transcripts encoding
glycolytic and mevalonate enzymes as well as the transferrin receptor (47,48). As discussed
above, these genes encode proteins that function in pathways needed to help the parasite satisfy
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its nutritional needs. It is, therefore, tempting to speculate that these changes in gene expression
act to compensate for either differences in the metabolism or amounts of these nutrients within
an infected cell.
The ability for the host to modulate nutrient pools is not only a property that the parasite may
co-opt but also represents a critical mechanism for the host to restrict parasite growth. As an
example, a key IFNγ effector gene in humans is indoleamine dioxygenase that functions to
catabolize tryptophan, which the parasite cannot synthesize de novo (32). Thus, tryptophan
starvation is a critical anti-toxoplasmotic pathway in some but not all hosts.
TOXOPLASMA MODULATION OF HOST CELL CYCLE
Regulating host cell cycle is a widely recognized mechanism for viruses to perfect their
intracellular lifestyle (49). Evidence also indicates that this is not restricted to viruses and many
microbial pathogens also manipulate their host's cell cycle. The most striking example among
Apicomplexan parasites is Theileria, which transforms its host cells to facilitate its replication
(50).
Two recent reports demonstrate that Toxoplasma is also able to dysregulate its host's cell cycle
and causes host cells to arrest at the G2/M border (51,52). This effect on the host cell cycle
was independent of the type of host cell and occurred in dividing and senescent cells (52).
Importantly, RNAi-mediated knockdown of a gene involved in regulating the host cell cycle
(UHRF1), which causes cells to arrest in G1, resulted in a significant reduction in parasite
growth (51). Initial characterization of a factor that modulates the host cell cycle during
infection indicated that it is a heat-labile factor larger than 10 kDa (53). Surprisingly, this factor
was secreted from infected cells and could act on neighboring uninfected cells. Why would
Toxoplasma want to affect the cell cycle of both infected and uninfected cells? One reason
could be that the parasite is acting extrinsically on neighboring cells to prepare them for
infection (53). Early studies supporting this hypothesis showed that Toxoplasma preferentially
infects cells in the S-phase (54–56). Alternatively, host cell structures with which the parasite
interacts (e.g. the MTOC) may not be accessible at other stages of the cell cycle (41,57).
TOXOPLASMA MODULATES HOST TRANSCRIPTION
Changes in host gene expression are among the most common and widespread that takes place
after infection. To understand the importance of these changes in Toxoplasma-infected cells,
several groups have used DNA microarrays to examine changes in transcript abundance after
infection (47,48,58). These experiments indicated that the expression levels of more than 1000
host genes were modulated. These genes encode proteins involved in many different processes
including inflammation, apoptosis, metabolism, and cell growth and differentiation. The
challenge to these types of studies is defining how each host gene contributes to the host-
pathogen interaction. As a first step, the genes were clustered into three functionally distinct
classes: (i) `pro-host' – host genes required for host defense, (ii) `pro-parasite' – host genes
required for parasite growth, and (iii) `bystander' – host genes incidentally regulated as a
consequence of modulating the first two classes (47).
Potential pro-parasite genes upregulated by infection included those encoding glycolytic
metabolic genes, transferrin receptor, and vascular endothelial growth factor. These candidate
pro-parasite genes are regulated by a single host transcription factor named hypoxia-inducible
factor 1 (HIF1) (59,60). HIF1, which is the key transcription factor in a cell's response to
decreased oxygen levels, is a heterodimer consisting of α and β subunits. Toxoplasma infection
activates HIF1 and loss of the HIF1α subunit leads to a significant reduction in parasite growth
at physiological oxygen levels (61). The parasite factor that activates HIF1 is currently
unknown but does not appear to be a byproduct of parasite oxygen consumption because other
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hallmarks of hypoxic stress responses were not evident in Toxoplasma-infected cells (61).
Rather HIF1 activation is mediated by a short-lived diffusible factor, which excludes a rhoptry-
derived factor. This conclusion is also supported by the finding that upregulation of the
transferrin receptor, which is another HIF1-target gene, is also mediated by a diffusible factor
(48).
Besides HIF1, other host genes that encode transcription factors involved in cell growth and
survival were also upregulated by infection. Among the earliest of these host genes were those
encoding subunits of the EGR and AP-1 transcription factors (62,63). In contrast to HIF1,
upregulation of one of these genes, EGR2, required direct contact between the host cell and
parasite and appears to involve a rhoptry-derived factor. EGR and AP-1 transcription factors
regulate genes involved in cell growth, survival, and differentiation. Given the well-
documented roles that the EGR and AP-1 transcription factors play in stress responses (64–
66), the activation of these stress response transcription factors may be important to help host
cells survive the stress of the infection.
Nuclear factor-κ B (NF-κB) is another transcription factor whose activity is modulated during
infection (67–70). Although parasite modulation of NF-κB is debated in the Toxoplasma field,
interest in this transcription factor was driven by two independent findings. First, loss of various
NF-κB subunits leads to greater susceptibility during both acute and chronic infections (71–
73). In addition, Toxoplasma prevents its host cell from undergoing apoptosis via NF-κB-
dependent expression of pro-apoptotic genes (67,74) (for a more detailed discussion of
Toxoplasma regulation of host cell apoptosis, we direct readers to an excellent recent review
(75)).
The NF-κB family is composed of five members: p50 (NF-κB1), p52 (NF-κB2), p65 (RelA),
RelB, and c-Rel (76). In unstimulated cells, homo- or hetero-dimers of NF-κB are sequestered
in the cytoplasm by a family of inhibitors, called IκBs (inhibitor of κ B). Activation of NF-
κB is initiated by the degradation of IκB proteins. This occurs primarily via activation of kinases
called IκB kinases (IKKs). When activated, IKK phosphorylates two serine residues in IκB,
which leads to its ubiquitination and degradation by the proteasome. The NF-κB complex is
then free to enter the nucleus where it can induce expression of specific genes that have NF-
κB-binding sites in their promoter (77).
Activation of NF-κB by Toxoplasma is an area of controversy. Type I strains can transiently
block NF-κB nuclear translocation in murine macrophages and human fibroblasts even though
IKK activation and IκB degradation is not inhibited (70). This block in NF-κB translocation
results in a decrease in the expression of inflammatory response genes such as IL-12p40 and
TNF-α (70,78). In contrast, NF-κB is in the nuclei of Toxoplasma-infected murine fibroblasts
and the transcription factor plays a role in the induction of anti-apoptotic genes (63,79). In
infected murine fibroblasts, IκBα is phosphorylated but remarkably does not appear to be
degraded (67). Instead, phosphorylated IκBα is found at the PVM where it may be
phosphorylated by a parasite-encoded kinase (67,80). Differences between these studies might
be due to different host cell types and/or host species being used but are most likely not due to
differences in parasite strains because these studies all used a type I strain. In other work,
however, differences in NF-κB activation have been associated with strain type: type II but
not type I strains induce nuclear translocation of NF-κB in murine splenocytes (81) and bone
marrow-derived macrophages (82). Furthermore, several microarray studies have
demonstrated that cells infected with type II parasites have higher levels of NF-κB-regulated
genes compared with uninfected cells (47,83).
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TOXOPLASMA–HOST COMMUNICATION DURING BRADYZOITE
DEVELOPMENT
The ability of Toxoplasma to establish a chronic, asymptomatic infection by converting into
transmissible tissue cysts that remain hidden from the host's immune system is an important
feature of the parasite's life cycle that allows it to be such a successful and wide-spread pathogen
(84). To establish a chronic infection, bradyzoites must form and the host must control
tachyzoite proliferation. Bradyzoite development is a complex process that consists of changes
in parasite gene and protein expression with the goal to slow its growth and escape detection
by the host's immune system (85). Thus, there is a decrease in the expression of immunogenic
surface proteins, metabolic enzymes, and an increase in the abundance of genes that act to
facilitate entry into Go.
In vitro, bradyzoite development can be triggered by factors that mimic immune-derived
stressors such as high pH, IFNγ, nitric oxide, high temperature, nutrient starvation, or by some
drugs used to treat Toxoplasma infections (31,86–88). Thus, the parasite senses stress signals
and uses these to develop into a persistent state that is relatively resistant to these stresses.
A role for the host cell in signaling tachyzoite to bradyzoite conversion was demonstrated by
taking advantage of a drug, a trisubstituted pyrrole, designated Compound 1, which stimulated
in vitro bradyzoite development (89). This drug acts by upregulating the abundance of the host
gene CDA1, whose over expression leads to cell cycle arrest.
In primary muscle cells and neurons Toxoplasma spontaneously differentiates with high
frequency into encysted bradyzoites, without the need for external stressors (90–92).
Interestingly, neurons and muscle cells are terminally differentiated and permanently
withdrawn from the cell cycle, which is in contrast to the typical cells most researchers use for
Toxoplasma experiments (e.g. primary fibroblasts, macrophages, Vero cells, etc.). Together,
these data suggest a model in which tachyzoite growth is favored inside of growing cells; but,
when tachyzoites cannot manipulate the host's cell cycle (e.g. CDA1 upregulation or infection
of terminally differentiated cells) bradyzoite development initiates. How the parasite senses
replicating from non-replicating cells is not clear. One possibility is that infection of a
terminally differentiated cells results in slower parasite growth, which is an important step in
bradyzoite development (93,94).
Changes in parasite gene expression are an important facet of bradyzoite development and
Toxoplasma surface proteins represent the largest group of stage-specific genes. For example,
tachyzoites predominantly express SAG1, SAG2a, SAG3, SRS1, SRS2, and SRS3. In contrast,
bradyzoites express a largely different repertoire of surface proteins including SAG2C,
SAG2D, SAG2X, SAG2Y, SRS9, and SAG4. Many of these surface proteins are immunogenic
and antibodies to them can be detected in sera from infected animals. SAG1 and SAG2 are
considered the most immunogenic tachyzoite surface proteins and are believed to be critical
in helping to limit tachyzoite proliferation (95–99). What the anti-Toxoplasma antibodies are
doing is less clear because FcγRII- or complement-deficient mice that receive sera from
infected mice are protected just as well as wild-type mice (100), suggesting that complement-
mediated lysis of parasites is not important. On the other hand, IgG purified from sera of
infected animals reduce parasite invasion, suggesting that these antibodies act by preventing
invasion, which is a critical step in the parasite's life cycle (95,100).
TOXOPLASMA ACTIVATION AND EVASION OF HOST IMMUNE RESPONSES
Anti-Toxoplasma immune responses are generated at two distinct times – acute infections after
a host is initially infected and reactivated infections after parasites are released from cysts.
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Regardless of when or where the immune system encounters Toxoplasma, IL-12 release by
dendritic cells, macrophages, and neutrophils is needed to stimulate IFNγ secretion from both
T-cells and NK cells (101,102).
IL-12 expression is triggered by Toxoplasma stimulating CCR5- and Toll-like receptor (TLR)-
dependent signaling. CCR5 is a chemokine receptor expressed by multiple cell types including
macrophages and dendritic cells (103). Mice lacking CCR5 express significantly lower
amounts of IL-12 after Toxoplasma infection and CCR5+ dendritic cells treated with
Toxoplasma extracts upregulate IL-12 (104,105). Subsequent biochemical purification
identified Toxoplasma cyclophillin-18 (C18) as a potential CCR5 ligand; but, the effect of C18
on CCR5-dependent IL-12 expression was relatively low, suggesting that other CCR5 ligands
may be important for IL-12 expression.
TLRs are a family of at least 13 proteins that function to recognize pathogen-associated
molecular patterns (106). TLR signaling is mediated by a series of adaptor proteins, the most
prominent of which is MyD88. Several TLRs including TLR2, TLR4, and TLR11 bind
Toxoplasma-derived factors (107–110). Unlike MyD88, which is essential for survival in
parasite-infected animals, loss of individual TLRs has minimal impact on survival (107,111–
113). These data indicate that either TLR signaling is functionally redundant or that MyD88
acts downstream of other receptors. These potential receptors include the IL-1 and IL-18
receptors both of which interact with MyD88 (114) and whose ligands are upregulated by
infection (115–118).
Because MyD88 is important for host resistance, significant effort has been placed on
identifying parasite-derived TLR ligands. Thus far, ligands for TLR11 (the actin-binding
protein profilin) as well as TLR2 and TLR4 (HSP70 and GPI lipid anchors) have been described
(107,108,110). In mice, profilin binding to TLR11 is most critical for stimulating IL-12
production (107,119). In addition, TLR11 is necessary for the development of CD4+ T-cell
responses to profilin (120). But it is not clear whether profilin is important in human disease
because TLR11 is not functionally expressed in humans (121).
Although MyD88 is critical for primary responses to infection, it is less clear what role it plays
in immunity to either reactivated or secondary infections. Mice lacking MyD88 specifically in
their T-cells are susceptible to intraperitoneal parasite infections (122). In addition, loss of
MyD88 blocks the ability for mice to develop Th1 responses when vaccinated with
Toxoplasma lysates (123). In contrast, MyD88 is not essential to develop protective immune
responses to oral infections in mice vaccinated with an attenuated parasite strain (124). The
basis for these differences is most likely due to the infection route (oral vs intraperitoneal) and
type of vaccination (lysate vs attenuated strain). Elucidating the mechanistic basis for these
differences is, however, critical for vaccine and drug development.
IFNγ, produced in response to parasite stimulation of IL-12 expression, is the critical cytokine
for resistance to both acute and chronic Toxoplasma infections (125–127). Several IFNγ
effectors important for resistance have been identified including the IFNγ-activated p47 family
of GTPases (LRG47, IGTP, and IRG47), nitric oxide synthase, and indoleamine dioxygenase
(32,128,129). These IFNγ target genes affect parasite growth by different mechanisms. For
example, the GTPases stimulate autophagy (130) and indoleamine dioxygenase sequesters
tryptophan (32). With the exception of indoleamine dioxygenase, loss of most of these effectors
in mice affects resistance to either acute or chronic infections, suggesting that they are
expressed at either temporally or spatially distinct phases.
Although these data have helped define how various IFNγ effectors protect against
Toxoplasma in mice, some effectors are not present in humans; humans only have one p47
family member (131) and iNOS and nitric oxide, which are important for resistance in mice,
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appear to have no significant role in protection in human cells (132,133). Thus, either the single
human GTPase can function in place of the murine isoforms or other IFNγ effectors are
important in humans. One possible candidate is indoleamine dioxygenase, which is critical for
resistance to Toxoplasma in human cells but does not appear to play any significant role in
murine-derived cells (134–136).
IFNγ regulates expression of its effector genes mainly through activation of the transcription
factor STAT1 (137). When IFNγ binds to its receptor it triggers the activation of Janus kinases
(JAK1 and JAK2). These kinases phosphorylate STAT1 on tyrosine701 residue, which
subsequently leads to its dimerization, nuclear import, and binding to promoters of genes that
contain consensus γ-activated sequence (GAS) sites. Some of the genes activated by STAT1
are other transcription factors such as interferon regulatory factor (IRF)-1 and the class II MHC
transactivator (CTIIA). STAT1 alone or in combination with other transcription factors (such
as IRF1) will induce the transcription of the effector genes important for resistance against
Toxoplasma.
Toxoplasma has developed ways to subvert IFNγ signaling thus allowing it to become a
successful and widespread pathogen. Indeed, Toxoplasma-infected cells are significantly less
responsive to IFNγ-induced upregulation of many genes, including MHC Class II, iNOS, and
the p47 GTPases (83,138). Because IFNγ activation of the STAT1 signaling pathway is
essential for the control of Toxoplasma growth, much effort has focused on how
Toxoplasma inhibits the STAT1-mediated transcription in IFNγ-stimulated cells. There is some
evidence that Toxoplasma inhibits STAT1 by upregulating levels of suppressor of cytokine
signaling (SOCS) proteins (139). SOCS are a family of eight proteins (SOCS1-7 and CIS) that
are well-recognized attenuators of IFNγ-dependent signaling (140). These proteins affect
IFNγ signaling by either inhibiting the catalytic activity of the JAKs (SOCS1, SOCS3) or by
inhibiting recruitment of STATs (CIS). Toxoplasma infection of macrophages upregulates the
abundance of SOCS-1, SOCS-3 and CIS mRNA levels. A role for these proteins in
Toxoplasma immune evasion was established by demonstrating that when parasites infected
macrophages stably overexpressing SOCS-1, SOCS-3, or CIS these macrophages could not
produce nitric oxide or limit parasite growth in response to IFNγ (139). Furthermore,
Toxoplasma has a reduced ability to downregulate IFNγ response genes (iNOS, MIG) in
IFNγ-activated macrophages from SOCS-1−/− mice. All these effects are dependent on viable
parasite invasion and correlated with the number of invasion events consistent with the
hypothesis that they are caused by a factor that Toxoplasma secretes into the host cell. These
downregulatory effects on IFNγ signaling were time-dependent and full inhibition was not
achieved until 24 h post-infection, suggesting that Toxoplasma does not directly interfere with
the initial IFNγ response but rather acts by up-regulating SOCS proteins (139). Supporting
such a mechanism was the observation that the levels of total STAT1 were reduced in
Toxoplasma-infected macrophages, which is consistent with the ability of SOCS to target
STAT1 for degradation (139). However, others have not observed any differences in total
STAT1 levels in Toxoplasma-infected cells stimulated with IFNγ (83,141). These studies
suggested that Toxoplasma interferes with the binding of STAT1 to GAS elements leading to
decreased expression of STAT1 responsive genes. The basis for these differences in the
mechanism underlying parasite inhibition of IFNγ is not clear, but could be because the work
showing decreased STAT1 expression used high doses of type I parasites (139), while the other
studies used lower doses of type II strains (83,141).
TOXOPLASMA DISSEMINATION IN THE HOST
Toxoplasma disseminates rapidly from the initial site of infection to secondary lymphoid
tissues and then on to other tissues (142,143). As the key cells that traffic from infected tissues
to the spleen and draining lymph nodes, dendritic cells are likely candidates as the `Trojan
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Horse' that Toxoplasma uses to disseminate. In support of this hypothesis, early in vitro studies
demonstrated that parasites preferentially infect and replicate inside of monocytes and dendritic
cells (144). In addition, infection of dendritic cells increased their migratory capacity (145–
147). Dendritic cell trafficking was pertussis toxin sensitive, suggesting that Giα-dependent
chemokine receptors are important for trafficking (147). Most importantly, parasitized
dendritic cells adoptively transferred to uninfected mice disseminated more quickly than
uninfected cells (147). A more detailed phenotyping of these dendritic cells surprisingly
revealed that they were not conventional dendritic cells but rather were a novel population of
CD11c+ cells that expressed both PDCA1 (a plasmacytoid dendritic cell marker) and CD11b
(a myeloid cell marker) (148).
The above experiments used in vitro and intraperitoneal infection models to examine dendritic
cell-based dissemination. But it is still not clear whether these dendritic cells are important for
dissemination after an oral infection. A useful model to test this may be a transgenic mouse
that expresses the diphtheria toxin receptor under control of the CD11c promoter. Injection of
these mice with diphtheria toxin depletes almost all dendritic cells (149). Dissemination of
GFP- or luciferase-expressing Toxoplasma could then be monitored in mock- or dipthera toxin-
treated mice. Unlike conventional plasmacytoid dendritic cells that are resistant to diphtheria
toxin because they express low levels of CD11c (150), the PDCA1+ cells in Toxoplasma-
infected mice should be sensitive to the toxin because they expressed high levels of CD11c
(151).
IMPACT OF PARASITE GENOTYPE ON TOXOPLASMA HOST SIGNALING
Toxoplasma isolates from humans and livestock in Europe and North America group primarily
into one of three clonal lineages (types I, II, and III) that can be discriminated in mice by their
virulence (152–154). Type I strains are very virulent (LD100 of one parasite). In contrast, types
II and III strains are less virulent (LD50 ~103 and ~105, respectively (155)). In humans, all
three lineages cause disease, but they appear to differ in the tissues they affect and when they
infect people. For example, type I strains are more often associated with post-natally acquired
ocular infections, whereas type II strains are more associated with congenital infections and
toxoplasmic encephalitis (156).
Recently, it has become more appreciated that the various Toxoplasma strains differ profoundly
in how they modulate host cell signaling pathways. For example, human foreskin fibroblasts
(HFFs) infected with types I, II, or III strains have significantly different gene expression
profiles (155). If the strain-specific regulation of a host gene has a genetic basis then it should
segregate among F1 progeny derived from a cross between two strains that differ in regulation
of that gene. Thus, human DNA microarrays were used to compare the transcriptional profile
of HFFs infected with 19 unique F1 progeny derived from crosses between types II and III
strains (157). These microarray experiments indicated that 3188 human cDNAs correlated with
the allelic state of specific Toxoplasma genomic loci. Interestingly, the expression levels of
1176 of these cDNAs correlated with a single locus on Toxoplasma chromosome VIIb. This
suggested that in the vicinity of that locus there was at least one polymorphic Toxoplasma gene
whose product had a major effect on HFF gene expression. Pathway analysis identified that
many of the host genes regulated by this locus were targets of the STAT6 and STAT3
transcription factors (158), suggesting that many of the differences in modulation of host gene
expression by the different Toxoplasma strains were due to differences in STAT3/6 signaling.
Data supporting this hypothesis included STAT3/6 activation for prolonged times in cells
infected with types I and III strains (155). In contrast, STAT3/6 were only transiently activated
in cells infected with type II strains. Subsequently, ROP16 was identified as the Toxoplasma
protein mediating the strain-specific differences in maintaining STAT3/6 activation. While the
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basis for the differences between the two ROP16 alleles is not yet known, it is not due to
differences in the expression, host cell secretion, or nuclear localization of either allele.
No other polymorphic parasite factors that regulate host gene expression are currently known.
However, the data suggest that at least one gene exists on each Toxoplasma chromosome that
is involved in the strain-specific regulation of host gene expression (155). Given the precedent
for rhoptry-localized kinases and kinase-like proteins (e.g. ROP16, ROP18, and ROP2, 3, 4)
as key mediators in regulating Toxoplasma host interactions, it is possible that other secreted
kinases may fill a similar role in regulating other host genes. Indeed, a search of the
Toxoplasma genome database (http://www.toxodb.org) predicts that more than 70 predicted
genes encode proteins that have signal peptides and have significant homology to protein
kinases (Fig. 1).
IMPACT OF PARASITE GENOTYPE ON TOXOPLASMA-INDUCED DISEASE
Virulence of type I strains is due in large part to over production of Th1 cytokines that cause
tissue damage (116,159,160). In addition, type I parasites display enhanced migratory capacity
across cellular barriers in vitro and in vivo, which may also contribute to virulence (161).
Similarly, a virulent strain (named S23) derived from a cross between types II and III strains
had a higher in vivo growth rate and disseminated more rapidly than an avirulent strain from
the same cross (named S22) (162).
Recently, Taylor et al. (163) used QTL mapping of F1 progeny from a type I×III cross and
identified a locus on chromosome VIIa that was tightly linked to virulence. The responsible
gene was subsequently identified as ROP18. ROP18 is a rhoptry-localized, functional serine/
threonine kinase that is secreted into host cells. Expression analysis indicated that ROP18
expression was significantly higher in type I than in type III strains. Importantly, transfer of
the type I allele into the non-virulent type III strain increased virulence by more than four orders
of magnitude. Virulence was dependent on the ROP18's kinase activity as transfer of a type I
kinase dead mutant into a type III strain did not increase virulence. Although it is not clear how
ROP18 functions, it is possible that its ability to increase parasite proliferation may enhance
virulence (163,164). Likewise, ROP18 substrates have yet to be identified although
recombinant ROP18 can phosphorylate an unknown 70-kDa parasite protein, but not proteins
in host cell extracts (164).
In a separate study, Grigg et al. (165) found that two out of 16 progeny from a cross between
avirulent types II and III strains were surprisingly more virulent than either parental strain or
other progeny. These differences in virulence were not due to faster growth because there were
no apparent differences in invasion or growth rates between the virulent and avirulent progeny
(165). To identify the virulence genes, mice were infected with the types II and III parental
strains and with 40 unique F1 progeny of a type II×III cross. QTL mapping from these
experiments identified five Toxoplasma genomic regions associated with virulence (VIR1–5)
(166).
Using a candidate gene approach, we identified VIR3 as ROP18, which was the same rhoptry
kinase identified by Taylor et al. (166). Subsequent sequence analysis of the ROP18 gene
(including promoter regions) from types I–III strains revealed that type III strains have a unique
2.1-kb sequence inserted 85 bp upstream of the ATG start codon. It seems likely that this
insertion (relative to types I and II) in the 5′-untranslated region – promoter of the type III
ROP18 allele is involved in the major difference in expression of this locus in type III strains
(163,166).
Expressing the type II ROP18 allele in a type III strain increased virulence by four orders of
magnitude (166), which is surprising because VIR3 was predicted to only account for ~10%
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of the variance in virulence between type II and III strains. One possible explanation for
ROP18's surprisingly high impact on virulence lies in the fact that in the transgenic type III:
ROP18II strain, ROP18 was expressed about eight times higher than in the wild-type type II
strain (166).
Using a similar candidate gene approach, VIR4 was identified as ROP16 on chromosome VIIb.
Interestingly, expression of a type I or III allele of ROP16 in a type II strain made that strain
less virulent. At the moment, it is unknown why the type II strain became less virulent but is
likely due to ROP16's role in sustained STAT3/6 activation (155).
The genes responsible for the VIR1, VIR2 and VIR5 QTLs have yet to be identified. VIR1 has
been mapped to a region spanning ~0.98 Mb on the left end of chromosome XII. Two
interesting candidate genes are found within this region: (i) a surface antigen (SAG3), and (ii)
a secreted rhoptry-localized putative protein kinase (ROP5). VIR2 falls within a ~1.2 Mb
interval on chromosome X, and contains 139 predicted genes. Two candidate genes in this
locus (genes 42.m03493 and 42.m03409 in the ToxoDB database) are both predicted to have
signal peptides and at least one transmembrane domain but lack homology to other known
proteins or domains. Finally, the VIR5 QTL is found in a region on chromosome XII where
there are very few differences between types II and III strains. It should also be noted that this
QTL is linked to resistance to adenosine arabinoside, which is due to a loss of function mutation
in the adenosine kinase gene (167). It has been reported that a lack of functional adenosine
kinase can result in fitness defects (168). Because the type III parent carries the adenosine
arabinoside marker and this drug was used to select 23 of the 41 recombinant progeny, it is
possible that adenosine kinase is the gene responsible for VIR5.
CONCLUSIONS
Although Toxoplasma was discovered over 100 years ago (169,170), we are only now
beginning to appreciate the importance of the role that parasite modulation of its host has on
parasite growth, bradyzoite development, immune evasion, and virulence. These discoveries
are significant not only because they taught us about Toxoplasma-specific processes but also
because they illuminate novel biological processes. Recent examples include hijacking of
microtubule-based LDL-trafficking, invasion via the RON complex, rhoptry injection of
virulence factors, and IFNγ-inducible GTPase-mediated autophagy. But many important
questions remain about how Toxoplasma grows within its host. The development of new
biochemical and genetic tools will facilitate studies to answer these questions. These tools
include high-throughput RNAi and small molecule inhibitor screens that have already yielded
important information about Toxoplasma invasion (171). In addition, the development of
cosmid libraries to identify mutated genes in forward genetic screens will now allow many
investigators to use chemical mutagenesis-based screens to identify parasite genes that
modulate host cell functions (172).
Besides the topics we covered in this review, future Toxoplasma research will likely focus on
understanding how epigenetic regulation of both parasite and host gene expression affect
communication between Toxoplasma and its host. In addition, recent evidence has indicated
that Toxoplasma infections can have significant effects on host behavior (173–176) and future
work will likely aim to elucidate the molecular basis for these changes. Finally, the long-term
goal of studying an important infectious disease like Toxoplasma is the development of
protective vaccines as well the production of effective drug therapies that have few side effects.
Understanding the basic biology underlying the interaction between Toxoplasma and its host
will greatly aid in reaching these goals.
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Fig. 1.
Overview of Toxoplasma host cell interactions. (A). Innate immune responses are initiated by
Toll-like receptor (TLR) and CCR5 recognition of Toxoplasma-derived factors. (B). Parasite
invasion is accomplished by the release of micronemal adhesins that interact with host surface
factors. This is then followed by rhoptry secretion that results in the formation of the moving
junction and in the release of parasite factors (e.g ROP2 family members, ROP16, ROP18, and
PP2c-hn) that either interact with the parasitophorous vacuole (PV) (ROP2 family and ROP18)
or are transported to the host cytoplasm (ROP16) or nucleus [PP2c-hn (177)]. Some of these
factors (ROP16 and ROP18) are polymorphic virulence factors. (C). Intracellular parasites
reorganize host mitochondria and endoplasmic reticulum as well as the host microtubule
organizing center and cytoskeleton around the PV. Host microtubules associated with LDL-
loaded cholesterol form membrane tubules that push into the PV and are wrapped with the
dense granule protein GRA7. (D). Small soluble nutrients freely diffuse across the PV and then
are taken up by the parasite presumably by membrane transporters. (E). Host transcription is
regulated either by the parasite directly activating host transcription factors or by the parasite
triggering host signaling cascades that culminate in activating the host transcription factors.
Changes in host gene expression can act to either promote parasite growth, immune evasion,
virulence, or bradyzoite development.
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